Amgen announced that a great phase III clinical trial in metastatic pancreatic cancer cases treated with the ganitumab (an antibody that blocks IGF1R) plus gemcitabine had been interrupted because the above assortment was not successful in increasing overall survival in comparison to gemcitabine alone [31]. Here, IGF1R is linked to familial pancreatic carcinoma.